IFRX Stock Forecast: InflaRx NV Price Predictions for 2026-2027
The median 12-month analyst price target for InflaRx NV is $8.32. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 11 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores InflaRx NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (66): Analysts have, on balance, been raising their forecasts.
Quality (2): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
IFRX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IFRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Sept 2026 | Needham | Initiates | Buy | $8.00 |
| 7 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $4.00 → $6.00 |
| 13 May 2026 | Raymond James | Upgrade | Strong Buy | $7.00 → $9.00 |
| 11 May 2026 | Cantor Fitzgerald | Maintains | Overweight | $2.00 → $4.00 |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | $6.00 → $8.00 |
| 21 Apr 2026 | Guggenheim | Reiterates | Buy | — |
| 20 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 30 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Dec 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 10 Nov 2025 | Guggenheim | Maintains | Buy | — |
| 2 Sept 2025 | HC Wainwright & Co. | Assumes | Buy | $6.00 |
| 29 May 2025 | Oppenheimer | Maintains | Outperform | — |
| 8 May 2025 | Oppenheimer | Initiates | Outperform | — |
| 29 Apr 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 26 Mar 2025 | Guggenheim | Maintains | Buy | — |
| 21 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IFRX.
This page is one stock. Monday covers all of them.
IFRX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
IFRX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, InflaRx NV returned −9.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
IFRX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.9×
- EV / EBITDA
- —
Cheaper than 72% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 1% of US stocks
- Return on equity
- −31.0%
- Return on assets
- −18.0%
- Dividend yield
- —
Higher than 28% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
InflaRx NV has a market value of $153.3M and an enterprise value of $42.4M.
Revenue in the twelve months to 30 June 2026: −$10K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$39.1M, a 387053.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$23.8M.
InflaRx NV employs 65 people — −$155.4 of revenue per employee.
Data provided by Twelve Data
IFRX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at IFRX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own InflaRx NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about IFRX
What is the IFRX stock price forecast for 2026-2027?
The median 12-month analyst price target for InflaRx NV is $8.32, with estimates ranging from $4.89 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IFRX stock a buy right now?
Of the 8 analysts covering InflaRx NV, 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InflaRx NV 11 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IFRX?
As at 21 Nov 2026, InflaRx NV ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (66 of 100).
Will IFRX stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts is $8.32, and Ticker Nerd's factor model ranks InflaRx NV 11 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IFRX stock forecast for 2030?
No analyst covering InflaRx NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IFRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.89 to $13 over the next 12 months.
How has IFRX stock performed over the past year?
InflaRx NV returned -9.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does InflaRx NV do?
InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing anti-inflammatory therapies that target the complement system, particularly the C5a and C5aR pathways. The company’s portfolio centers on proprietary antibody and small-molecule programs designed to address autoimmune and other inflammatory diseases through precise modulation of immune signaling.
About InflaRx NV.
InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing anti-inflammatory therapies that target the complement system, particularly the C5a and C5aR pathways. The company’s portfolio centers on proprietary antibody and small-molecule programs designed to address autoimmune and other inflammatory diseases through precise modulation of immune signaling. Its current pipeline includes vilobelimab, an intravenously administered anti-C5a antibody, and an oral C5aR inhibitor in development for inflammatory indications. InflaRx serves the biotechnology and healthcare sectors, with research and operational activities in Germany and the United States. The company’s work is centered on advancing novel treatments for severe inflammatory conditions where targeted complement inhibition may play an important therapeutic role.
CEO Prof. Niels C. Riedemann M.D., Ph.D. · 65 employees · Germany · https://www.inflarx.de